Atrial Natriuretic Peptide

Tan, Adriaan C.; Rüssel, Frans G. M.; Thien, Theo; Benraad, Theo J.

doi:10.2165/00003088-199324010-00003

Cited by 37 publications

(4 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacokinetics of ANP are characterized by a short plasma half-life and high clearance. Two phases are observed in the plasma disappearance curve (two compartments) in a range of dose ( Tan et al, 1993 ). Cinaciguat (BAY 58–2667) is a class of soluble guanylate cyclase activator molecule.…”

Section: Introductionmentioning

confidence: 99%

Study of the Effect of Treatment With Atrial Natriuretic Peptide (ANP) and Cinaciguat in Chronic Hypoxic Neonatal Lambs on Residual Strain and Microstructure of the Arteries

Navarrete

Chen

Aranda

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Study of the Effect of Treatment With Atrial Natriuretic Peptide (ANP) and Cinaciguat in Chronic Hypoxic Neonatal Lambs on Residual Strain and Microstructure of the Arteries

Navarrete

Chen

Aranda

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

“…Due to the large size of proteins and peptides, they usually exhibit small volumes of distribution, limited by the volume of the extracellular space, due to their mobility and inability to pass through membranes [14,15]. However, binding to intravascular/extravascular proteins or active tissue uptake can significantly increase the volume distribution of biologics [16]. The pharmacokinetics of proteins and peptides are usually described by a two compartment model, and volume of distribution of the central compartment as well as the steady-state volume of distribution (Vss) are usually reported [17].…”

Section: Introductionmentioning

confidence: 99%

Pediatric Dosing and Body Size in Biotherapeutics

Shi

Derendorf

2010

Pharmaceutics

View full text Add to dashboard Cite

Although pediatric doses for biotherapeutics are often based on patients' body weight (mg/kg) or body surface area (mg/m2), linear body size dose adjustment is highly empirical. Growth and maturity are also important factors that affect the absorption, distribution, metabolism and excretion (ADME) of biologics in pediatrics. The complexity of the factors involved in pediatric pharmacokinetics lends to the reconsideration of body size based dose adjustment. A proper dosing adjustment for pediatrics should also provide less intersubject variability in the pharmacokinetics and/or pharmacodynamics of the product compared with no dose adjustment. Biological proteins and peptides generally share the same pharmacokinetic principle with small molecules, but the underlying mechanism can be very different. Here, pediatric and adult pharmacokinetic parameters are compared and summarized for selected biotherapeutics. The effect of body size on the pediatric pharmacokinetics for these biological products is discussed in the current review.

show abstract

“…However, NPR-C only contains a 37 amino acid cytoplasmic domain compared to the large ~500 amino acid cytoplasmic domain for guanylyl cyclases. NPR-C appears to function in the internalization and degradation of bound natriuretic peptides (Nussenzveig et al, 1990) and is thought to contribute significantly to the short half-life (1-4 min) of ANP in plasma (Maack et al, 1993;Tan et al, 1993). In addition, however, numerous investigators have reported coupling of NPR-C to signal transduction pathways in tissue homogenates or cell lines [reviewed by Levin (1993)].…”

mentioning

confidence: 99%

The Disulfide Linkages and Glycosylation Sites of the Human Natriuretic Peptide Receptor-C Homodimer

Stults¹,

O'Connell²,

Garcia³

et al. 1994

Biochemistry

View full text Add to dashboard Cite

The natriuretic peptide receptor-C (NPR-C) constitutes greater than 95% of the natriuretic peptide binding sites in vivo. This cell surface glycoprotein is a disulfide-linked homodimer with a subunit molecular weight of 68,000. Two sources and types of ANP affinity-purified human NPR-C were used to map disulfide linkages and glycosylation sites of this receptor by mass spectrometry: the extracellular domain obtained by papain cleavage of a receptor-IgG fusion protein expressed in Chinese hamster ovary cells, and a baculovirus/Sf9-expressed cytoplasmic truncation mutant in which 34 of 37 cytoplasmic domain amino acids were deleted. Two intramolecular disulfide bonded loops were found in the 435 amino acid extracellular domain (C63-C91, C168-C216). The juxtamembrane residues C428 and C431 are involved in homodimer formation, confirmed by site-directed mutagenesis of full-length NPR. Three of the four potential Asn-linked glycosylation sites are occupied: N41 (complex), N248 (high mannose), and N349 (complex; partial occupancy). These data describe the intra- and intermolecular linkages in NPR-C, providing a model for the homologous guanylyl cyclase receptors, NPR-A and NPR-B; both of the cyclase receptors likely contain the first amino-terminal 29 amino acid loop, but only NPR-A possesses the second 49 amino acid loop in common with NPR-C.

show abstract

Atrial Natriuretic Peptide

Cited by 37 publications

References 157 publications

Study of the Effect of Treatment With Atrial Natriuretic Peptide (ANP) and Cinaciguat in Chronic Hypoxic Neonatal Lambs on Residual Strain and Microstructure of the Arteries

Study of the Effect of Treatment With Atrial Natriuretic Peptide (ANP) and Cinaciguat in Chronic Hypoxic Neonatal Lambs on Residual Strain and Microstructure of the Arteries

Pediatric Dosing and Body Size in Biotherapeutics

The Disulfide Linkages and Glycosylation Sites of the Human Natriuretic Peptide Receptor-C Homodimer

Contact Info

Product

Resources

About